BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · 4th Quarter - Report

STRONGBRIDGE BIOPHARMA PLC

via SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

4th Quarter (Oct 1 - Dec 31) · 2018Posted Jan 22, 2019Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: STRONGBRIDGE BIOPHARMA PLC
Description: Pharmaceutical Company
Location: Pennsylvania · United States of America

Registrant

Firm: SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
Description: Law Firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Issues related to pharmaceutical development, commercialization, and pricing.
LobbyistsAVIA DUNN · JOHN BENTIVOGLIO
TargetedSENATE

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

STRONGBRIDGE BIOPHARMA PLC — Lobbying — Receipts Report